Tigwa Davis, Ph.D.

Senior Director, Health Economics and Outcomes Research

Tigwa Davis headshot - up close headshot of a man in a suit soft smiling

Tigwa Davis, Ph.D., has extensive experience designing and leading real-world evidence (RWE) and observational research studies for biotechnology and pharmaceutical organizations using commercially available data sources and electronic health records.

Prior to joining Inovalon, he served as Senior Principal Investigator, Scientific Director, and Vice President of Science at Health Analytics, LLC, where he helped shape the organization’s growth and scientific strategy. His research spans a broad range of therapeutic areas, including mental health, neurological and neurodevelopmental disorders, and immunological diseases.

Tigwa also has significant experience designing and executing studies that evaluate the safety, quality, and performance of medical devices to support compliance with European Union legislation and safety standards. His work has been published across a range of scientific and therapeutic areas, including chronic and rare diseases.

Earlier in his career, he served as a Senior Scientist in Neurobiology at the American Type Culture Collection (ATCC) and as an Assistant Professor of Biology at Georgetown University.

Tigwa holds a Ph.D. in Pharmacology from the University of Michigan, completed a postdoctoral fellowship in Neuroscience at the University of California, San Francisco, and earned a Bachelor of Science in Biology from Morehouse College.

Authored Content

pharmacist using mobile device at pharmacy
Life Sciences

Oncology Drug Shortages and the Impact of Price Erosion

If you’re feeling the pain and financial impact of increased audits and appeals, you’re not alone. Expedited resolutions start with smarter workflows and all-payer integration. Check out this infographic for concrete steps to take to boost the success rates and efficiency of your audit and appeals processes.

Read More →
Placeholder
Ophthalmology, social drivers of health

Sociodemographic and Clinical Characteristics of Latanoprostene Bunod Initiators Among Medicare Fee-for-Service Patients With Open Angle Glaucoma and Ocular Hypertension

Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research. Findings available upon request. Contact us for more information.

Placeholder
Epilepsy

Examining the Impact of Comorbid Depression on Healthcare Utilization, Cost, and Outcomes in Patients With Newly Diagnosed Epilepsy in the U.S.

Accepted for presentation at American Academy of Neurology. Findings available upon request. Contact us for more information.

Placeholder
Real-world evidence

Real-World Adherence Patterns of Latanoprostene Bunod Ophthalmic Solution 0.024% in Medicare Patients With Comorbid Dry Eye Disease

Accepted for presentation at Academy of Managed Care Pharmacy. Findings available upon request. Contact us for more information.

Placeholder
Real-world evidence

Real-World Adherence Patterns of Latanoprostene Bunod Ophthalmic Solution 0.024% in Medicare Patients With Comorbid Dry Eye Disease

Accepted for presentation at American Society of Cataract and Refractive Surgery. Findings available upon request. Contact us for more information.

Placeholder
Epilepsy

Impact of Depression on Outcomes and Treatment Patterns in Patients With Newly Diagnosed Epilepsy: A Retrospective Claims Analysis

Accepted for presentation at American Epilepsy Society. Findings available upon request. Contact us for more information.